Canada should give biopharmaceutical firms patent term extensions to recover time lost due to mandatory regulatory and marketing approvals.
Canadian policy-makers should enact legislation to define rare diseases and encourage Canadian firms to intensify their research and development of new therapies, writes Kristina Lybecker. Victor Casale photograph courtesy of Flickr
VANCOUVER, B.C. / Troy Media/ – As the old adage states, “You’ll be known by the company you keep.” As such, the implications for Canada’s biopharmaceutical sector are rather dismal.
People. Policy. Politics. This is an exclusive subscriber-only story.
David MacNaughton 'made it a priority' to understand who the key U.S. influencers were and which Canadian would be best to deliver the message, says former PMO Canada-U.S. war room staffer Diamond Isinger.
'The evidence showed there were many ways in which Mr. Trudeau, either directly or through the actions of those under his direction, sought to influence the Attorney General,' the commissioner's report says.